Research and Markets: Global CNS Drug Market: Strategic Assessments of Leading Suppliers

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/cc678b/global_cns_drug_ma) has announced the addition of the "Global CNS Drug Market: Strategic Assessments of Leading Suppliers" report to their offering.

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global CNS Market.

The report provides a worldwide strategic overview of the pharmaceutical market, including:

  • Sales forecast for major product segments: ethical, OTC, generics.
  • Sales forecast for major drug categories.
  • Sales forecasts by geographical region: North America, Europe, Japan, Latin America.

In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies.

The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.

The report's major objectives include:

  • To establish a comprehensive, factual, annually updated and cost-effective information based on performance, capabilities, goals and strategies of the leading players in the global CNS drug market.
  • To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a-vis the leading competitors.
  • To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
  • To complement organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.

For more information visit http://www.researchandmarkets.com/research/cc678b/global_cns_drug_ma



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.